Pharmacokinetic study of amrubicin in lung cancer patients with impaired hepatic function

Trial Profile

Pharmacokinetic study of amrubicin in lung cancer patients with impaired hepatic function

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Amrubicin (Primary)
  • Indications Lung cancer; Non-small cell lung cancer; Small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 12 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top